Data Driven Design of Alginate Hydrogels for the Delivery of Spinal Cord Injury Therapeutics
Hydrogels are among the most versatile platforms for controlled drug delivery, yet identifying a formulation that produces a desired release profile remains a slow, largely empirical process. This is particularly limiting for alginate, whose release behavior emerges from the nonlinear interplay of polymer molecular weight, concentration, guluronate content, crosslinking cation, and gelation kinetics. This dissertation develops and validates an automated, machine learning-guided framework that navigates this design space efficiently and then applies it to two fragile biologics relevant to spinal cord injury (SCI): the matrix-degrading enzyme chondroitinase ABC (chABC) and the neurotrophin brain-derived neurotrophic factor (BDNF). Using a liquid-handling robot, a seed library of 120 alginate formulations loaded with bovine serum albumin (BSA) was prepared and its release measured. A Gaussian process regression model, trained under an implicit scheme to predict cumulative release over time, was interrogated with Shapley additive explanations, which identified time, alginate molecular weight, and alginate concentration as the dominant determinants of release. Bayesian active learning with an expected-improvement acquisition function then drove successive formulation generations toward near zero-order kinetics. Critically, the top BSA-optimized formulations transferred without further optimization to the sustained release of active chABC single-enzyme nanoparticles (chABC-SENs), demonstrating that surrogate-derived formulations generalize to a labile therapeutic enzyme. To enable minimally invasive co-delivery, four clinically relevant shear-thinning hydrogels were screened for chABC-SEN compatibility. Hydrophobically associated networks abolished enzymatic activity, whereas a hydrophilic alginate-hyaluronic acid (alg-HA) matrix preserved it, establishing hydrophobicity as a critical and previously underappreciated design parameter. The alg-HA platform supported sustained co-release of active chABC-SEN alongside immunoreactive BDNF, which followed a biphasic profile reaching approximately 78% by day 11. Together, these studies deliver a generalizable, data-driven strategy for hydrogel formulation optimization and a compatible injectable vehicle for co-delivering a matrix-degrading enzyme and a neurotrophic factor, providing a foundation for combination therapies for spinal cord injury.
Authors
- Chee Meng Eugene Cheong
Publication Details
- Journal
- Rutgers University Community Repository (Rutgers University)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.7282/t3-dckm-6s05
- Primary Topic
- Hydrogels: synthesis, properties, applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00